Rocket Pharmaceu Financials

RCKT

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2025 Currency USD FYE December

This page shows Rocket Pharmaceu (RCKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Revenue

Rocket Pharmaceu generated $0 in revenue in fiscal year 2024.

EBITDA

-$266.0M

YoY-62.2%

Rocket Pharmaceu's EBITDA was -$266.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 62.2% from the prior year.

Free Cash Flow

-$215.6M

YoY-67.4%

Rocket Pharmaceu generated -$215.6M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 67.4% from the prior year.

Net Income

-$258.7M

YoY-53.0%

Rocket Pharmaceu reported -$258.7M in net income in fiscal year 2024. This represents a decrease of 53.0% from the prior year.

EPS (Diluted)

$-2.73

YoY-2.2%

Rocket Pharmaceu earned $-2.73 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 2.2% from the prior year.

Cash & Debt

$163.6M

YoY-29.7%

5Y CAGR+55.3%

Rocket Pharmaceu held $163.6M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

106M

YoY+65.0%

5Y CAGR+73.4%

Rocket Pharmaceu had 106M shares outstanding in fiscal year 2024. This represents an increase of 65.0% from the prior year.

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

R&D Spending

$171.2M

YoY+36.5%

5Y CAGR+62.9%

Rocket Pharmaceu invested $171.2M in research and development in fiscal year 2024. This represents an increase of 36.5% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$5.9M

YoY-23.1%

5Y CAGR+50.5%

Rocket Pharmaceu invested $5.9M in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 23.1% from the prior year.

RCKT Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY18
Revenue	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$171.2M+36.5%	$125.5M+19.0%	$105.4M+82.1%	$57.9M+8.7%	$53.3M+257.1%	$14.9M
SG&A Expenses	$102.0M+144.1%	$41.8M+44.7%	$28.9M+58.2%	$18.2M+2.0%	$17.9M+268.4%	$4.9M
Operating Income	-$273.2M-63.4%	-$167.2M-24.5%	-$134.3M-76.4%	-$76.2M-7.0%	-$71.2M-259.9%	-$19.8M
Interest Expense	$1.9M-36.6%	$3.0M-57.3%	$7.0M+16.9%	$6.0M-1.3%	$6.0M	$0
Income Tax	$0	N/A	N/A	N/A	N/A	N/A
Net Income	-$258.7M-53.0%	-$169.1M-21.0%	-$139.7M-80.8%	-$77.3M-3.7%	-$74.5M-280.6%	-$19.6M
EPS (Diluted)	$-2.73-2.2%	$-2.67-6.0%	$-2.52-59.5%	$-1.58	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Revenue	$0	$0	$0	$0	$0	$0	$0	$0
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$34.1M-20.1%	$42.7M+18.7%	$35.9M-13.9%	$41.7M-10.9%	$46.8M-8.8%	$51.4M+10.8%	$46.4M-7.3%	$50.0M
SG&A Expenses	$18.4M-26.7%	$25.0M-12.0%	$28.4M+32.1%	$21.5M+15.9%	$18.6M+7.0%	$17.4M+9.8%	$15.8M-16.9%	$19.0M
Operating Income	-$52.2M+26.6%	-$71.1M-10.5%	-$64.4M-1.8%	-$63.3M+3.3%	-$65.4M+4.8%	-$68.8M-10.6%	-$62.2M+10.0%	-$69.1M
Interest Expense	$473K0.0%	$473K+0.2%	$472K+0.4%	$470K+0.2%	$469K+0.2%	$468K0.0%	$468K0.0%	$468K
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$50.3M+27.0%	-$68.9M-12.4%	-$61.3M-2.8%	-$59.7M+3.6%	-$61.9M+5.8%	-$65.7M-12.6%	-$58.3M+12.6%	-$66.7M
EPS (Diluted)	$-0.45+27.4%	$-0.62-10.7%	$-0.56+9.7%	$-0.62+17.3%	$-0.75+8.5%	$-0.82-12.3%	$-0.73+18.0%	$-0.89

RCKT Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY18
Total Assets	$527.7M+6.2%	$497.0M-15.9%	$590.8M+58.8%	$372.1M+48.1%	$251.3M+1147.4%	$20.1M
Current Assets	$378.2M-3.5%	$392.1M-19.6%	$487.3M+58.4%	$307.8M+47.2%	$209.1M+1003.1%	$19.0M
Cash & Equivalents	$163.6M-29.7%	$232.7M-21.7%	$297.1M+60.3%	$185.4M+66.5%	$111.4M+513.8%	$18.1M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M+27.1%	$30.8M0.0%	$30.8M0.0%	$30.8M0.0%	$30.8M	$0
Total Liabilities	$64.5M+52.4%	$42.3M-51.6%	$87.3M+34.7%	$64.8M+13.2%	$57.3M+1137.6%	$4.6M
Current Liabilities	$40.7M+83.5%	$22.2M-32.0%	$32.6M+78.1%	$18.3M+19.1%	$15.4M+240.0%	$4.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$463.2M+1.9%	$454.7M-9.7%	$503.5M+63.9%	$307.3M+58.4%	$194.0M+1150.3%	$15.5M
Retained Earnings	-$1.2B-147.6%	-$491.9M-52.4%	-$322.8M-76.3%	-$183.1M-73.0%	-$105.9M-237.7%	-$31.4M

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Total Assets	$368.0M-12.6%	$421.0M-10.6%	$471.1M-16.8%	$566.3M-5.4%	$598.8M+29.7%	$461.8M-10.3%	$514.8M-6.7%	$551.8M
Current Assets	$227.7M-17.9%	$277.2M-14.6%	$324.5M-14.2%	$378.2M-15.4%	$446.9M+43.2%	$312.1M-7.7%	$338.0M-7.1%	$364.1M
Cash & Equivalents	$75.9M+131.4%	$32.8M-34.1%	$49.8M-10.9%	$55.9M-75.2%	$225.7M+400.6%	$45.1M-30.2%	$64.6M-54.0%	$140.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M0.0%	$39.2M-0.1%	$39.2M
Total Liabilities	$54.4M-18.6%	$66.8M+13.3%	$58.9M-20.1%	$73.8M+27.9%	$57.7M-1.9%	$58.8M+5.2%	$55.9M-10.0%	$62.1M
Current Liabilities	$31.2M-28.2%	$43.4M+22.9%	$35.3M-27.2%	$48.5M+44.9%	$33.5M-2.5%	$34.3M+10.1%	$31.2M-20.3%	$39.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$313.7M-11.4%	$354.2M-14.1%	$412.1M-16.3%	$492.6M-9.0%	$541.1M+34.3%	$403.0M-12.2%	$458.9M-6.3%	$489.7M
Retained Earnings	-$1.4B-3.7%	-$1.3B-5.4%	-$1.3B-33.4%	-$959.4M-6.6%	-$899.7M-7.4%	-$837.8M-8.5%	-$772.1M-8.2%	-$713.8M

RCKT Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY18
Operating Cash Flow	-$209.7M-73.1%	-$121.2M-62.3%	-$74.6M-15.4%	-$64.7M-20.2%	-$53.8M-237.0%	-$16.0M
Capital Expenditures	$5.9M-23.1%	$7.6M-63.0%	$20.6M-11.4%	$23.3M+1501.4%	$1.5M+91.2%	$760K
Free Cash Flow	-$215.6M-67.4%	-$128.8M-35.2%	-$95.2M-8.3%	-$87.9M-59.2%	-$55.2M-230.3%	-$16.7M
Investing Cash Flow	$131.7M+598.6%	$18.9M+119.5%	-$96.6M-147.6%	-$39.0M-640.0%	-$5.3M-593.7%	-$760K
Financing Cash Flow	$185.7M+392.9%	$37.7M-86.7%	$283.0M+59.2%	$177.8M+15.8%	$153.5M+504.2%	$25.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$72K	$0	$0	$0

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Operating Cash Flow	N/A	N/A	-$55.8M	N/A	N/A	N/A	-$57.6M	N/A
Capital Expenditures	N/A	N/A	$364K	N/A	N/A	N/A	$3.0M	N/A
Free Cash Flow	N/A	N/A	-$56.2M	N/A	N/A	N/A	-$60.6M	N/A
Investing Cash Flow	N/A	N/A	-$58.0M	N/A	N/A	N/A	-$36.7M	N/A
Financing Cash Flow	N/A	N/A	$0	N/A	N/A	N/A	$18.3M	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

RCKT Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-49.0%-15.0pp	-34.0%-10.4pp	-23.6%-2.9pp	-20.8%+8.9pp	-29.6%+67.5pp	-97.2%
Current Ratio	9.30-8.4	17.69+2.7	14.94-1.9	16.81+3.2	13.60+9.4	4.19
Debt-to-Equity	0.14+0.0	0.09-0.1	0.17-0.0	0.21-0.1	0.300.0	0.30
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24	Q4'23
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	-13.7%+2.7pp	-16.4%-3.4pp	-13.0%-2.5pp	-10.5%-0.2pp	-10.3%+3.9pp	-14.2%-2.9pp	-11.3%+0.8pp	-12.1%
Current Ratio	7.30+0.9	6.39-2.8	9.19+1.4	7.80-5.6	13.35+4.3	9.09-1.7	10.83+1.5	9.29
Debt-to-Equity	0.17-0.0	0.19+0.0	0.140.0	0.15+0.0	0.11-0.0	0.15+0.0	0.120.0	0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Financial Health Signals

Piotroski F-Score Weak

1/9

Financial strength trend (9 signals). 7-9 = strong, 0-3 = weak.

Earnings Quality Low Quality

0.81x

Operating cash flow vs net income. Above 1.0x = cash-backed earnings.

Interest Coverage At Risk

-144.9x

Operating income vs interest expense. Above 5x = safe, below 2x = risky.

Similar Companies

Larimar Therapeutics Inc LRMR

$266.7M

Immuneering Corp IMRX

$320.3M

AUTOLUS THERAPEUTICS PLC AUTL

$367.3M

Diamedica Therapeutics Inc DMAC

$449.4M

Assembly Bioscie ASMB

$412.7M

Frequently Asked Questions

What is Rocket Pharmaceu's annual revenue?

Rocket Pharmaceu (RCKT) reported $0 in total revenue for fiscal year 2024. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Is Rocket Pharmaceu profitable?

No, Rocket Pharmaceu (RCKT) reported a net income of -$258.7M in fiscal year 2024.

What is Rocket Pharmaceu's earnings per share (EPS)?

Rocket Pharmaceu (RCKT) reported diluted earnings per share of $-2.73 for fiscal year 2024. This represents a -2.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

What is Rocket Pharmaceu's EBITDA?

Rocket Pharmaceu (RCKT) had EBITDA of -$266.0M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.

What is Rocket Pharmaceu's free cash flow?

Rocket Pharmaceu (RCKT) generated -$215.6M in free cash flow during fiscal year 2024. This represents a -67.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Rocket Pharmaceu's operating cash flow?

Rocket Pharmaceu (RCKT) generated -$209.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Rocket Pharmaceu's total assets?

Rocket Pharmaceu (RCKT) had $527.7M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Rocket Pharmaceu's capital expenditures?

Rocket Pharmaceu (RCKT) invested $5.9M in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How much does Rocket Pharmaceu spend on research and development?

Rocket Pharmaceu (RCKT) invested $171.2M in research and development during fiscal year 2024.

How many shares does Rocket Pharmaceu have outstanding?

Rocket Pharmaceu (RCKT) had 106M shares outstanding as of fiscal year 2024.

What is Rocket Pharmaceu's current ratio?

Rocket Pharmaceu (RCKT) had a current ratio of 9.30 as of fiscal year 2024, which is generally considered healthy.

What is Rocket Pharmaceu's debt-to-equity ratio?

Rocket Pharmaceu (RCKT) had a debt-to-equity ratio of 0.14 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Rocket Pharmaceu's return on assets (ROA)?

Rocket Pharmaceu (RCKT) had a return on assets of -49.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Rocket Pharmaceu's cash runway?

Based on fiscal year 2024 data, Rocket Pharmaceu (RCKT) had $163.6M in cash against an annual operating cash burn of $209.7M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Rocket Pharmaceu's Piotroski F-Score?

Rocket Pharmaceu (RCKT) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals.

Are Rocket Pharmaceu's earnings high quality?

Rocket Pharmaceu (RCKT) has an earnings quality ratio of 0.81x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation.

Can Rocket Pharmaceu cover its interest payments?

Rocket Pharmaceu (RCKT) has an interest coverage ratio of -144.9x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline.